论文部分内容阅读
目的 :研究 HL A- I、HL A- DR及 ICAM- 1在 JO- RRP细胞膜中表达的免疫及临床意义。方法 :用免疫组化SP法检测 5 4例 JO- RRP,2 0例 AO- RRP和 2 0例喉癌组织中 HL A- I、HL A- DR及 ICAM- 1的表达。结果 :HL A- I在JO- RRP的表达有下降 ,阳性率为 46 .3% ;AO- RRP的 HL A- I表达 (80 .0 % )明显高于 JO- RRP(P<0 .0 1) ,喉癌表达则明显较少 (15 .0 % ) (P <0 .0 2 5 )。 HL A- DR在 6例 (11.1% ) JO- RRP中表达 ,与 AO- RRP及喉癌的表达均无显著性差异 (P >0 .0 5 )。 ICAM- 1在侵袭性 JO- RRP和喉癌中各有 2例阳性表达 ,而非侵袭性 JO- RRP和 AO- RRP中则无一例阳性。结论 :JO- RRP的发病与宿主的免疫密切相关 ,研究 HL A分子的多态性以及 ICAM- 1的表达对了解 JO-RRP的免疫状况有意义。但由于免疫系统的复杂性 ,从单一的免疫指标 HL A- I、HL A- DR、ICAM- 1尚不能对 JO- RRP的发展和预后作出明确的判断
Objective: To study the immunological and clinical significance of HL-I, HL-DR and ICAM-1 expression in JO-RRP cell membrane. Methods: The expression of HL-I, HL-DR and ICAM-1 in 54 cases of JO-RRP, 20 cases of AO-RRP and 20 cases of laryngeal carcinoma were detected by immunohistochemical SP method. RESULTS: The HL-I expression decreased in JO-RRP with a positive rate of 46.3%. HL-I expression (80.0%) in AO-RRP was significantly higher than that in JO-RRP 1), while the expression of laryngeal carcinoma was significantly less (15.0%) (P <0.05). The expression of HL-DR in 6 cases (11.1%) JO-RRP was not significantly different from that in AO-RRP and laryngeal carcinoma (P> 0.05). ICAM-1 expression was positive in 2 cases of invasive JO-RRP and laryngeal carcinoma, while none of non-invasive JO-RRP and AO-RRP was positive. CONCLUSIONS: The incidence of JO-RRP is closely related to the host immune system. Studying the polymorphism of HL A molecule and the expression of ICAM-1 is of significance to understand the immune status of JO-RRP. Due to the complexity of the immune system, however, it is impossible to make a clear judgment on the development and prognosis of JO-RRP from the single immune indicators HL A- I, HL A- DR and ICAM- 1